ARPM brought together regulators and pharmaceutical producers to discuss issues of the single EAEU market

A meeting “Future of the EAEU market. National legislations and their application within the Eurasian Economic Union”. The meeting was organized by the Association of the Russian Pharmaceutical Manufacturers and took place at the International Industry Exhibition INNOPROM 2016.

India, the country with one of the world’s fastest-growing economy, was the partner of INNOPROM. Indian companies were presented by the head of marketing and sales of Avantage, Ksitidzh Gururani. Cooperation of the Indian pharmaceutical market with the EAEU has a great potential. Indian Pharma will benefit from single registration and production rules, the decrease in logistic and customs fees. Now Indian companies can easily enter the Russian market, which will benefit patients. However, according to Ksitidzh Gururani, there are still issues to be worked on. There is still no system of medical registration and mutual registration recognition, also, the so-called law “odd man out” works to the disadvantage of foreign companies on the Russian market. 

The Russian producers supported the necessity to optimize the registration process shortly. The “Odd mad out” act, however, was viewed positively by the Russian producers. “The main goal of the act was to support local producers in Russia. However, our task is to invite foreign companies to bring their production to Russia and, therefore, to create new jobs and affordable medicines,” said ARPM Director General, Victor Dmitriev.

Mr. Dmitriev reminds the audience about unresolved issues regarding the act. There are still differences in interpretation of the act. For example, the Federal Antimonopoly Service and the Ministry of Industry and Trade have different views regarding consideration as domestically produced medicines of those that were only packaged in Russia.

Finally, the Russian producers shared positive results of local medicine production. Alexander Petrov, a member of the healthcare committees in the State Duma and Chairmen of the Board of the Ural Biomedical Cluster, noted that overall production of the cluster increased by 40% in the past year, and continues to grow. However, statistic shows that procurement does not always increase with the production increase. Mr. Petrov thinks that this situation has to improve.

ARPM invites all to continue the discussion regarding the act “Odd man out” at the meeting between CCI, RSPP and ARPM during the Western Economic forum on September 2. Members of the State Duma, the Health Ministry, Federal Antimonopoly Service, the Roszdravnadzor and pharmaceutical companies were invited to participate in the meeting. The primary agenda of the meeting is to discuss the issues of the CT-1 certificate.

Пресс-служба АРФП